The early treatment of acute myocardial infarction has become characterised by aggressive regimens aimed at limiting infarct size, the rapid treatment of arrhythmias and left ventricular dysfunction, and early evaluation for surgery or angioplasty. Intravenous thrombolytic (fibrinolytic) agents have become the mainstay of treatment for definite infarction and significant mortality and morbidity gains have been demonstrated with these drugs in a number of major studies. flow in infarct related vessels.6 The intravenous agent achieved the same end, haemorrhagic complications being reduced by employing a short duration infusion.7
Background
Thrombolysis began in 1933 when Tillet and Garner first isolated a fibrinolytic substance, which they called streptococcal fibrinolysin, from haemolytic streptococci. 1 Christensen and Macleod renamed this substance streptokinase in 1945 and described its mechanism of action as converting plasminogen to plasmin which lyses fibrinogen and fibrin in coagulum. 2 It was initially used clinically to debride infected tissue spaces such as chronic empyema and haemothorax. 3 The purified streptokinase produced by Christensen after 1947 became used in early experiments which showed that prolonged intravenous infusion could dissolve intracoronary thrombus and 4 limit infarct size.
Little progress was made for the next two decades because of fears over systemic side effects, especially bleeding and allergy, and because attention was focused on the establishment of coronary care units (CCU) within most major hospitals-an initiative which itself led to significant mortality gains.
The current era began in 1980 when DeWood reported the use of coronary angiography to demonstrate thrombus within the coronary arteries of patients soon after the onset of acute myocardial infarction symptoms.5 Until that time it had not been appreciated that coronary thrombosis was the underlying pathological process in the majority of cases of myocardial infarction. The natural history of myocardial infarction involves recanalisation of the occluded artery so that intracoronary thrombus was often not seen at necropsy in patients who had died some days after the acute event. Intracoronary streptokinase was found to be effective in re-establishing blood Benefits of thrombolysis Early treatment with a thrombolytic agent lyses thrombus within coronary arteries and promotes recanalisation. Beneficial effects include limitation of infarct size, improved left ventricular function, and reduced mortality.
Surprisingly, the first report of mortality reduction with intravenous streptokinase comes from as long ago as 1958.4 Small studies carried out in the 1960s and 1970s supported these early findings, although concerns over side effects restricted widespread uptake. Several very large, placebo controlled trials reported survival benefits with the three principle thrombolytic agents in the 1980s. [10] [11] [12] [13] The most extensive description on mortality reduction appeared two years ago when the Fibrinolytic Therapy Trialists (FIT) Collaborative Group published an important review of all nine trials with more than a 1000 patients randomised per trial. Outcome data on almost 60 000 patients showed that thrombolysis reduced 35 day mortality after acute myocardial infarction from 11.5% to 9.6%, saving 20 to 30 lives per thousand treatments, depending on delay to treatment.14 Limiting the extent of ischaemic necrosis reduces the risk from left ventricular dysfunction, the principal cause of early and late nonarrhythmic mortality and morbidity. Left ventricular ejection fraction, albeit an inexact measure shortly after acute myocardial infarction, is improved by thrombolysis. 15 The frequency of dangerous arrhythmia is also reduced, probably by improving the blood supply to the highly arrhythmogenic "penumbra" of critically ischaemic myocardium surrounding the infarcting area.
Improved outcomes depend upon prompt reperfusion of ischaemic myocardium. Suc- cessful reperfusion is clinically apparent as an improvement in chest pain accompanied by ECG evidence of at least a 50% reduction in ST segment elevation. There is also a rapid rise and fall in cardiac enzyme levels in the plasma. Failure to achieve reperfusion may indicate the need to repeat the infusion or refer for urgent angiography.
Adverse effects Adverse events are extremely frequent after thrombolytic therapy, particularly when treatment is delayed or given inappropriately. Cardiac Patient selection All patients presenting with a history suggestive of acute myocardial infarction are potential candidates for fibrinolytic therapy, but many do not receive the treatment.'7 A major factor in treatment denials may be confusion over eligibility. The large international studies of the 1980s were inconsistent in terms of exclusion criteria, and up to two thirds of patients were excluded in some trials. For example GISSI'0 included only patients with definite infarction, while ISIS 21l and ASSET13 included patients with suspected acute myocardial infarction. The AIMS investigators'2 employed an upper age limit of 70 years and both AIMS and ISAM18 excluded patients with chest pain of more than six hours duration. By contrast there was no upper age limit with GISSI or ISIS 2, and patients were randomised up to 12 and 24 hours respectively after symptom onset. There was also inconsistency between trials with regard to inclusion of patients with cardiogenic shock and those who had had previous acute myocardial infarction.
Contradictory results between studies added to the difficulties of interpretation. In GISSI no benefit was demonstrated with streptokinase after six hours, whereas the ISIS 2 investigators showed significant mortality gains up to 12 hours after onset of chest pain. Results from ISIS 2 also showed improved survival with streptokinase in inferior myocardial infarction whereas no such benefit was seen in ISAM or GISSI. Mortality rates in patients with suspected acute myocardial infarction presenting with left bundle branch block (LBBB) were reduced from 28% to 14% in ISIS 2, whereas no significant difference was reported in this subgroup by the GISSI investigators.
The effect of thrombolysis allocation on subgroups distinguished by presenting features was examined in the FTT review of trials. '4 The odds ratios for death were significantly reduced in patients less than 75 years old presenting within 12 hours of onset of chest pain who had either ST segment elevation or LBBB on the ECG. Other subgroups are considered below.
ELDERLY PATIENTS
Acute myocardial infarction is twice as common in patients over the age of 75 years and is more often fatal. The mortality of acute myocardial infarction over the age of 75 is five times that of the under 55 years group. There is no evidence to suggest that larger infarctions are responsible for the excess mortality. Necropsy data from the GISSI 2 study revealed a higher incidence of cardiac rupture in fatal cases over the age of 70 compared to those under 60 years of age.'9 Although the percentage mortality reduction with thrombolysis is less in the older age group, the absolute numbers of lives saved is greater. In the FTT review of trials, this mortality reduction reached statistical significance up to age 74, with a trend for improved survival in thrombolysis allocated patients over 75 years of age. Another subgroup analysis suggested that one life was saved for 33 thrombolytic treatments in the over 75 years age group, compared with one life saved per 50 treatments in younger patients.20 The available evidence does not, therefore, support the adoption of an upper age limit for thrombolysis although in practice older patients often have other contraindications to treatment.
HYPERTENSION
The data are inconsistent with regard to the utility of thrombolytics in hypertensive patients. The FTT review of trials reported a non-significant trend in favour of treatment, but the confidence limits were wide. The major risk in this group is haemorrhagic stroke and there is some agreement that the agents should be avoided with systolic pressures over 180 mm Hg. However, transient hypertension will often respond to treatment with opiate analgesia, nitrates, or intravenous 3 blockers where indicated.
HYPOTENSION
Systolic blood pressures of less than 100 mm Hg occur most frequently after anterior acute myocardial infarction. Pooled data presented in the FTT review of trials suggest that thrombolytic therapy is beneficial, reducing mortality from 35.1% in controls to 28.9% in the treated group (P < 0.01). Control group mortality is higher than average in this subgroup so the absolute number of lives saved is even greater than the percentage reduction suggests. With severe hypotension or cardiogenic shock (clinically apparent as systemic hypotension plus pulmonary oedema) the case for thrombolysis remains to be proved.
PREVIOUS ACUTE MYOCARDIAL INFARCTION
Twenty per cent of patients admitted with acute myocardial infarction will have had a previous infarction and second and subsequent infarctions carry a greater risk of death. The reported mortality reduction from 14.1% to 12.5% with fibrinolysis in patients with prior myocardial infarction therefore represents more lives saved per treatment than in patients with first acute myocardial infarction. Streptokinase is contraindicated in the first two years after a previous dose and there is evidence of persistence of neutralising antibodies for at least four years.2' rt-PA is preferred in these circumstances.
INFERIOR INFARCTION
In acute inferior wall infarction with ST segment elevation thrombolytic therapy reduced 35 day mortality from 8.4% to 7.5% in the FTT review of trials, indicating a trend for improved survival with treatment that did not quite reach statistical significance.
There were different interpretations between the component trials: ISAM failed to show mortality gains with streptokinase after inferior acute myocardial infarction, whereas the ISIS 2 investigators reported significant benefit. Relatively low control group mortality after inferior infarction (8.4% v 16.9% for anterior acute myocardial infarction) may account for these differences. Inferior wall infarctions tend to be smaller (by number of leads involved) than anterior infarctions. The number of lives saved by fibrinolysis after inferior infarctions is similar to that observed with smaller anterior infarctions.
OTHER ECG FEATURES
Acute ST elevation is not universal with myocardial infarction. Acute myocardial infarction may present with ST segment depression, for example, or the ECG may be normal. Broadening the criteria to include patients with suspected acute myocardial infarction would enable more rapid thrombolysis in a proportion of patients but the data do not support the use of thrombolytic agents in these circumstances. Subdivision of patients into ECG categories widens the confidence limits, however, and some have argued that no evidence of benefit is not evidence of no benefit. 22 Others have indicated that, while coronary occlusion mediates acute transmural infarction (presenting with ST elevation), intermittent platelet plugs may be the cause of non-Q-wave acute myocardial infarction. The latter are more rationally treated with heparin and aspirin.23 This view gains support from the findings of the LATE study in which late presenters with non-diagnostic ECGs had a poorer outcome with thrombolysis than without. 24 Chest pain of non-cardiac origin is more likely in patients without the typical ECG changes of acute myocardial infarction. Pericarditis, peptic ulcer disease, and aortic dissection may all present with cardiac-type pain. In the ASSET study the mortality rate among patients given rt-PA for non-ischaemic chest pain was 9.6% compared with 1.2% for placebo. 13
LATE PRESENTERS
The benefits of thrombolysis are very much time dependent. Very early clot lysis among patients in the TEAHAT29 and GREAT30 studies prevented the development of full thickness changes in a proportion of patients, indicating a small window of opportunity during which a thrombolytic agent may reverse the process of infarction itself.
In the GISSI study the mortality gain in the first hour after onset of MI symptoms was 47 lives saved per 1000 treatments, reducing to 17 in the third to sixth hours. At more than six hours no significant difference was observed. By contrast, in ISIS 2 benefit was observed up to 24 hours after randomisation but in this study patients were not excluded if the exact time of symptom onset was unknown. Figure 1 shows the relation between absolute benefit (survival without disabling stroke) and time to treatment in 45 000 patients with ST elevation or bundle branch block.'4 Loss of benefit per hour of delay was 1.6 (SD 0.6) per 1000 patients treated. Benefit was still observed beyond the six hours interval, however. In 22 000 patients randomised 7-12 hours after onset of symptoms, mortality was reduced by thrombolysis from 12.7 % to 11.1% (P < 0.01).
Two other recent studies bear out these find- ficult to determine the exact time of onset of continuous pain in patients presenting with this type of history. Furthermore, even after the process of infarction has begun there may still be some advantage to treating with a thrombolytic agent. Infarct limitation and ventricular salvage are not relevant at this stage-benefits are related to secondary events. Scar formation and remodelling of infarcted areas is more complete in thrombolytic treated patients, leading to fewer dysrrhythmias and less risk from cardiac failure and ventricular aneurysm formation.
Provided there are no other contraindications, therefore, fibrinolysis may be attempted up to 12 hours after the onset of chest pain, even later in cases with a good history and diagnostic ECG.
Choice of agent
In UK practice streptokinase is the principal drug for in-hospital thrombolysis. It is given as a solution of 1.5 MU in 100 ml of normal saline over one hour. The drug costs approximately £85 per dose (recommended NHS price). Concomitant therapy is with oral aspirin 300 mg daily indefinitely and subcutaneous heparin 5000 units three times daily or 12 500 units twice daily until the patient is ambulant. For prehospital use anistreplase (APSAC) is preferred. This agent is similar to streptokinase but has been chemically modified to permit bolus administration: complexing streptokinase with acylated human lysoplasminogen allows a more rapid onset and prolonged half life. APSAC begins clot lysis within minutes and the effect lasts for four to six hours. It is much more expensive than streptokinase, at £495 per dose. The dosage regime is 30 units reconstituted in 10 ml of diluent given by slow intravenous injection over five minutes.
Recombinant tissue plasminogen activator (rt-PA), the costliest alternative at £750, is the agent of choice where there is known allergy to or previous use of streptokinase. rt-PA is a naturally occurring serine protease protein and is manufactured by recombinant DNA techniques. It is more clot specific than streptoki-nase and binds to fresh intravascular thrombus. It was previously given over three hours (10 mg bolus followed by 50 mg over one hour then 40 mg over two hours). More recently an accelerated or "front loaded" schedule has been employed: a 15 mg bolus dose followed by a maximum 50 mg (0.75 mg/kg) over 30 minutes, then a maximum 35 mg (0.5 mg/kg) over one hour. Concomitant treatment includes oral aspirin and intravenous heparin in a 5000 unit bolus then 1000 units/h for a minimum 48 hours, aiming for an APTT of 60-85 seconds.
Several important comparative studies were reported in the late 1980s, including GISSI 2 which compared streptokinase and rt-PA with and without heparin32 and ISIS 3, in which all three agents were compared.'6 At the time rt-PA was the most popular fibrinolytic in North America, mainly because of the TIMI 1 study of 1986 which showed far superior patency rates for infarct related arteries with rt-PA: 62% were patent on the 90 minute angiogram versus 31 % for streptokinase.33 However, this study had been terminated early and European cardiologists challenged its conclusions on the basis that early recanalisation, which may be transient, is an inadequate outcome measure.
This transatlantic "Battle of the Clotbusters"34 seemed to have been settled when ISIS 3 reported in 1992. Among more than 41 000 patients randomised between streptokinase, APSAC, and rt-PA in 914 hospitals, there was no significant difference in 35-day mortality. The findings are summarised in fig 2. Further evidence in favour of the continued use of streptokinase as agent of choice came from GISSI 2, which also failed to demonstrate survival benefit with rt-PA in its study of 20 891 patients. Mortality from acute myocardial infarction in these international megatrials was approximately 10% regardless of choice of thrombolytic agent. There was a much higher rate of cerebral haemorrhage with rt-PA in the ISIS 3 study (0.7% v 0.3%, P = 0.0001) though the difference was not significant in GISSI 2 (0.4% v 0.3%).
Despite these data, many North American cardiologists continued to favour rt-PA, citing methodological problems with the megatrials, including outcome differences between European hospitals and their US counterparts, the choice of two different brands of rt-PA, and the delayed subcutaneous heparin regime. Proponents of rt-PA regained some ground with the publication of the GUSTO (global utilisation of streptokinase and TPA for occluded coronary arteries) study. This international study involving 41 021patients randomised to four treatment groups reported lower mortality in the group receiving accelerated treatment with rt-PA and intravenous heparin than in the other three groups: streptokinase plus intravenous heparin, streptokinase plus subcutaneous heparin, and rt-PA plus streptokinase.35 Despite an increased rate of haemorrhagic stroke (0.72% v 0.54%) there was absolute benefit with rt-PA amounting to nine additional survivors without disabling stroke per 1000 patients treated. The greatest survival benefit was observed in the predetermined subsets who presented within four hours of chest pain onset, who were aged less than 75 years, and who had sustained anterior infarction. The mechanism of benefit was shown to relate to increased rates of early recanalisation.
In an angiographic subgroup of 2431 GUSTO patients, there was a higher rate of 90 minute patency in the rt-PA treated patients, although interestingly this was not sustained at 180 36 minutes.
In common with all the major studies, GUSTO has been criticised on methodological grounds. Although it was a prospective randomised controlled trial, GUSTO employed an open label study design. Also, in the data analysis, the streptokinase plus subcutaneous heparin arm was combined with the streptokinase plus intravenous heparin arm. Inconsistencies between study groups have also been noted, including the fact that there was more intervention in the rt-PA group and that excess survivors with rt-PA were only reported in US treated patients. 37 In light of the high cost of rt-PA, the additional stroke risk and the lack of demonstrable benefit from the agent in the systemic review of major trials, including GUSTO, rt-PA has not become the agent of choice in the United Kingdom. Instead many regional cardiology advisory groups offer guidelines for its use which are similar to those in table 3. Outside of these limited indications for rt-PA, streptokinase remains the thrombolytic agent of first choice.
Systems for timely thrombolysis
Several elements contribute to treatment delays, such as the time taken for the patient to seek medical help, the response time of the emergency services, and transfer time to hospital. Once in hospital the "door to needle time", Thrombolysis should be considered in all patients presenting with cardiac chest pain lasting more than 30 minutes for up to 12 hours after symptom onset. ECG criteria include ST elevation of at least 1 mm in limb leads and/or at least 2 mm in two or more adjacent chest leads or left bundle branch block. There is no upper age limit. All patients should also receive oral aspirin and subcutaneous (intravenous with rt-PA) heparin. Other adjuvant treatments have been reviewed previously in this journal. 48 Streptokinase is the drug of choice except where there is persistent hypotension, previous streptokinase or APSAC at any time, known allergy to streptokinase, or a recent proven streptococcal infection. In these circumstances the patient should receive rt-PA. Additional indications for rt-PA, based on subset analysis by the GUSTO investigators, include patients with ALL of the following: age less than 75 years, presentation within four hours of symptom onset, and ECG evidence of anterior acute myocardial infarction.
Treatment should be initiated as soon as possible. The greatest benefit is observed in patients treated early, pain to treat intervals of less than one hour make possible mortality reductions of nearly 50%. " When" matters more than "where": fast tracking to the CCU is one option but A&E initiated thrombolysis is feasible and timely. Prehospital thrombolysis is appropriate in certain geographical situations.
The development of practical guidelines for thrombolysis represents the most comprehensive example of evidence based medicine. 
